Oxa(IV)@ZnPc@M (+) + anti-PD-L1 exerted the strongest antitumor effect among all groups, with primary tumor shrinkage rate up to 94% compared with PBS (+) group, and the least increase in luminescence intensity of bone metastatic tumors compared to all groups (Fig. 6c–e). Here, CD274 is linked to metastatic neoplasm.